BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it
has received Notice of Allowance from the United States Patent Office for US Patent Application No.: 14/173,846 titled “ISOLATED CELLS AND POPULATIONS COMPRISING SAME FOR THE TREATMENT OF CNS DISEASES”.
The allowed claims cover methods of treating amyotrophic lateral sclerosis (ALS) and Parkinson’s disease using mesenchymal stem cells that secrete neurotrophic factors, including glial derived neurotrophic factor (GDNF).
“We continue to protect our technology through strategic intellectual property achievements and this Notice of Allowance from the USPTO is a welcome addition to our IP portfolio,” commented BrainStorm’s CEO Chaim Lebovits.
This patent is the result of Brainstorm’s ongoing development of NurOwn® that initiated at the Tel Aviv University, neuroscience laboratory of Prof. Dani Offen, the company’s chief scientific advisor.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 70 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the company’s website at www.brainstormcell.com.
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
LifeSci Advisors LLC
Matt Middleman, M.D.
LifeSci Public Relations, LLC